- Home
- NOTE vs SER Comparison
NOTE vs SER Comparison
Compare NOTE & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- SER
- Stock Information
- Founded
- NOTE 2013
- SER 2017
- Country
- NOTE United States
- SER United States
- Employees
- NOTE N/A
- SER N/A
- Industry
- NOTE EDP Services
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- NOTE Technology
- SER Health Care
- Exchange
- NOTE Nasdaq
- SER Nasdaq
- Market Cap
- NOTE 39.9M
- SER 42.0M
- IPO Year
- NOTE N/A
- SER 2018
- Fundamental
- Price
- NOTE $2.14
- SER $3.86
- Analyst Decision
- NOTE Strong Buy
- SER Strong Buy
- Analyst Count
- NOTE 4
- SER 2
- Target Price
- NOTE $29.25
- SER $13.00
- AVG Volume (30 Days)
- NOTE 251.5K
- SER 25.5K
- Earning Date
- NOTE 11-06-2025
- SER 11-13-2025
- Dividend Yield
- NOTE N/A
- SER N/A
- EPS Growth
- NOTE N/A
- SER N/A
- EPS
- NOTE N/A
- SER N/A
- Revenue
- NOTE $102,673,000.00
- SER $116,000.00
- Revenue This Year
- NOTE N/A
- SER $134.46
- Revenue Next Year
- NOTE $4.61
- SER N/A
- P/E Ratio
- NOTE N/A
- SER N/A
- Revenue Growth
- NOTE N/A
- SER N/A
- 52 Week Low
- NOTE $2.05
- SER $3.70
- 52 Week High
- NOTE $24.36
- SER $7.92
- Technical
- Relative Strength Index (RSI)
- NOTE 18.97
- SER 31.36
- Support Level
- NOTE $2.50
- SER $3.86
- Resistance Level
- NOTE $3.28
- SER $4.18
- Average True Range (ATR)
- NOTE 0.33
- SER 0.33
- MACD
- NOTE -0.14
- SER -0.05
- Stochastic Oscillator
- NOTE 7.94
- SER 4.56
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.